Publications
Publications
Show Results For
-
All HBS Web
(619)
- Faculty Publications (235)
Page 1 of
235
Results
→
- September 2023
- Case
TetraScience: Noise and Signal
By: Thomas R. Eisenmann and Tom Quinn
In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from...
View Details
Keywords:
Entrepreneurship;
Business Growth and Maturation;
Business Organization;
Restructuring;
Forecasting and Prediction;
Digital Platforms;
Analytics and Data Science;
AI and Machine Learning;
Organizational Structure;
Network Effects;
Competitive Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States;
Boston
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing...
View Details
- April 2023
- Case
Drive Capital: A New Road for Venture
By: Paul A. Gompers and Alicia Dadlani
Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing...
View Details
- January 2023
- Case
Vertex and the Cure for Type 1 Diabetes
By: Amitabh Chandra, William J Anderson and Silvia Mare
Keywords:
Biotechnology Industry
- October 2022 (Revised May 2023)
- Case
Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues
Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But...
View Details
- March 2022
- Teaching Note
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008.
View Details
Keywords:
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information Technology;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Technology Adoption;
Biotechnology Industry;
Biotechnology Industry;
United States;
California;
Puerto Rico;
Rhode Island
- July–August 2021
- Article
Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes
By: Annamaria Conti and Maria P. Roche
We assess the heterogeneous impact of economic downturns on individuals’ decisions to bring high-technology ideas to the market in the form of new ventures. We thereby examine how worsening labor market conditions influence individuals’ opportunity costs of starting...
View Details
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly...
View Details
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...
View Details
Keywords:
Digital Technologies;
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Information Technology;
Technology Adoption;
Biotechnology Industry;
Biotechnology Industry;
United States;
California;
Puerto Rico;
Rhode Island
- January 2021
- Case
Takeda Pharmaceutical Company Limited (A)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn...
View Details
- January 2021
- Supplement
Takeda Pharmaceutical Company Limited (B)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and...
View Details
- January 2021 (Revised June 2023)
- Case
Biobot Analytics
In 2017, Newsha Ghaeli and Mariana Matus were deciding whether to leave their labs at the Massachusetts Institute of Technology, put other job opportunities aside, and dive full-time into founding a wastewater analysis start-up, Biobot. Ghaeli, an architect, and Matus,...
View Details
Keywords:
Entrepreneurship;
Information Technology;
City;
Analytics and Data Science;
Personal Development and Career;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
United States;
Kuwait;
Korean Peninsula
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)...
View Details
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
- October 2020 (Revised April 2022)
- Case
When Institutions Fail: HIV/AIDS in the 1980s
By: Tom Nicholas and Christian Godwin
During the early 1980s, young gay men in urban centers such as San Francisco and New York City began contracting a mysterious illness that would come to be known as HIV/AIDS. A diagnosis meant almost certain death, with a less than 1% survival rate. Conflicting...
View Details
Keywords:
Ethics;
Policy;
Government and Politics;
Health Pandemics;
History;
Rights;
Media;
Organizations;
Business and Community Relations;
Religion;
Social Psychology;
Identity;
Prejudice and Bias;
Social Issues;
Public Opinion;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
United States
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After...
View Details
Keywords:
Pharmaceutical Companies;
Biotech;
Health Care;
Entrepreneur;
Innovation;
International Business;
Entrepreneurial Finance;
Entrepreneurship;
Finance;
Innovation Strategy;
Venture Capital;
Strategy;
Cross-Cultural and Cross-Border Issues;
Biotechnology Industry;
Biotechnology Industry;
Tokyo
- 2020
- Book
Work, Mate, Marry, Love: How Machines Shape Our Human Destiny
By: Debora L. Spar
Covering a time frame that ranges from 8000 BC to the present, and drawing upon both Marxist and feminist theories, the book argues that nearly all the decisions we make in our most intimate lives—whom to marry, how to have children, how to have sex, how to think about...
View Details
Keywords:
Innovation;
Family;
Women;
Reproduction;
Artificial Intelligence;
Robots;
Gender;
Demography;
History;
Innovation and Invention;
Relationships;
Society;
Information Technology;
AI and Machine Learning;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry;
Africa;
Asia;
Europe;
Latin America;
North and Central America
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development...
View Details
- March 2020 (Revised June 2020)
- Case
Social Salary Setting at Spiber
By: Ashley Whillans and John Beshears
Can a “set your own salary” system boost employee happiness and motivation? Spiber made synthetic silk built from proteins mimicking the proteins found in spider silk, the world’s toughest known material by weight. Kazuhide Sekiyama and Junichi Sugahara established...
View Details